论文部分内容阅读
目的探讨FLAG方案治疗成人难治复发急性髓系白血病(AML)的疗效及安全性。方法对21例成人难治复发AML患者采用FLAG方案化疗,观察疗效及不良反应。结果 21例中完全缓解10例,部分缓解4例,总有效率为66.7%,病死率为19.1%。FLAG方案的不良反应主要为骨髓抑制及继发感染等,统计分析显示年龄、高白细胞数、多次复发是影响治疗效果的因素。结论 FLAG方案对成人难治复发AML的治疗缓解率相对较高,但骨髓抑制作用较强,有待进一步改进。
Objective To investigate the efficacy and safety of FLAG regimen in the treatment of refractory recurrent acute myeloid leukemia (AML) in adults. Methods Twenty-one patients with refractory relapsed AML were treated with FLAG chemotherapy, and the curative effect and adverse reactions were observed. Results In 21 cases, 10 cases were completely relieved and 4 cases partially relieved. The total effective rate was 66.7% and the mortality rate was 19.1%. The adverse reactions of FLAG regimen were mainly myelosuppression and secondary infection. Statistical analysis showed that age, high white blood cell count and multiple recurrence were the factors affecting the therapeutic effect. Conclusion The remission rate of FLAG regimen is relatively high in the treatment of refractory relapsed adult patients with AML, but the myelosuppression is stronger and need to be further improved.